HC Wainwright & Co. Reiterates Buy on scPharmaceuticals, Maintains $18 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on scPharmaceuticals (NASDAQ:SCPH) and maintained an $18 price target.
June 08, 2023 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on scPharmaceuticals and maintains an $18 price target.
The reiteration of a Buy rating and maintenance of an $18 price target by HC Wainwright & Co. analyst Douglas Tsao indicates a positive outlook for scPharmaceuticals. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100